EISAI INDIA AND MYLAN ENTER INTO CO-EXCLUSIVE MARKETING AGREEMENTTO COMMERCILIZE TECERIS® THE SECOND ERIBULIN BRAND IN INDIA


  • TECERIS® aimed at expanding access to metastatic breast cancer patients in India
[Vishakhapatnam, Bengaluru - India, September, 2019 /] -- Eisai Pharmaceuticals India Pvt. Ltd (a subsidiary company of Eisai Co., Ltd., Headquarters: Tokyo, CEO: Haruo Naito, “Eisai India”) and Mylan Pharmaceuticals Pvt Ltd. (Mylan), today jointly announced that they have entered into a marketing license agreement to commercialize TECERIS®, the Innovator’s second brand of the anticancer agent Eribulin mesylate (eribulin) in India. TECERIS® will be manufactured and supplied by Eisai India and marketed by Mylan. This agreement is an important strategy for expanding the access of eribulin for the treatment of metastatic breast cancer (MBC) patients in India.

Eribulin, a novel anticancer agent, discovered in-house by Eisai was approved in India in April 2013 for the treatment of locally advanced or metastatic breast cancer which previously was being treated with at least two chemotherapy regimens including an anthracycline and a taxane. In October 2013, Eisai India launched the eribulin brand Halaven®for eligible patients under its patient assistance programme.


Commenting on the co-exclusive, marketing relationship, Dr.Sanjit Singh Lamba, Managing Director, Eisai India said, “Our endeavor at Eisai group always has been to ensure that we make our innovative products more accessible to patients who have an unmet medical need. We have been doing it through our tiered pricing programs and now we have entered into a partnership with Mylan to address unmet medical needs. This step is a part of our hhc philosophy of human health care thereby keeping the patient at the center and ensuring our medicines are accessible and affordable.”

Commenting on the partnership, Mr. Rakesh Bamzai, President, India and Emerging Markets, Mylan said, “The launch of the innovator’s second brand of Eribulin, TECERIS® will enable enhanced access to the medicine through our co-exclusive marketing relationship as both Eisai India and Mylan share a commitment to bring affordable and high-quality medicines to market, especially in areas of unmet need. Eribulin is an important addition to our growing oncology portfolio and, expands the available treatment options for women with advanced or metastatic stages of breast cancer. The collaboration with Eisai India is yet another positive step in our ongoing efforts to help improve affordability and access to essential oncology treatments in India and serve the patient community.

The number of women diagnosed with breast cancer in India has increased in the recent years, with an estimated 163,000 new cases of breast cancer and approximately 87,000 related deaths in 2018.1 Breast cancer is now the most frequently diagnosed cancer in Indian women.1

Eisai group positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. In addition, Eisai group will continue to adopt proactive measures aimed at increasing access to its innovative pharmaceutical products in emerging countries and the developing world in order to contribute to an increase in the benefits provided to local patients and their families.

The partnership between Eisai India and Mylan will lead to enhanced access and affordability of cancer treatment for breast cancer patients in India. Mylan’s oncology portfolio in India includes high quality, affordable cancer-related cytotoxic and targeted therapies for breast, lung and colorectal cancer. 💢💢
 

Popular posts from this blog

மக்கள் படை கட்சியின் 2026 சட்டமன்ற வேட்பாளர் பட்டியல் வெளியீடு – பொதுச் செயலாளர் ராம்பிரகாஷ் அறிவிப்பு

𝘊𝘩𝘦𝘯𝘯𝘢𝘪 𝘏𝘰𝘴𝘵𝘴 64𝘵𝘩 𝘈𝘎𝘔 & 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘊𝘰𝘯𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘰𝘧 𝘍𝘦𝘥𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘗𝘢𝘱𝘦𝘳 𝘛𝘳𝘢𝘥𝘦𝘳𝘴 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘐𝘯𝘥𝘪𝘢 (𝘍𝘗𝘛𝘈)

THANC Hospital Opens 'Chennai Breast Centre' | Focuses on Women's Health & Breast Cancer Awareness

𝘒𝘢𝘶𝘷𝘦𝘳𝘺 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘝𝘢𝘥𝘢𝘱𝘢𝘭𝘢𝘯𝘪 𝘐𝘯𝘵𝘳𝘰𝘥𝘶𝘤𝘦𝘴 𝘍𝘳𝘦𝘦 𝘔𝘰𝘣𝘪𝘭𝘦 𝘓𝘶𝘯𝘨 𝘊𝘭𝘪𝘯𝘪𝘤 – “𝘒𝘢𝘶𝘷𝘦𝘳𝘺 𝘉𝘳𝘦𝘢𝘵𝘩 𝘊𝘩𝘦𝘤𝘬” 𝘧𝘰𝘳 𝘊𝘩𝘦𝘯𝘯𝘢𝘪 & 𝘚𝘶𝘳𝘳𝘰𝘶𝘯𝘥𝘪𝘯𝘨 𝘈𝘳𝘦𝘢𝘴

𝘗𝘢𝘶𝘭𝘴𝘰𝘯𝘴 𝘉𝘦𝘢𝘶𝘵𝘺 & 𝘍𝘢𝘴𝘩𝘪𝘰𝘯 𝘗𝘷𝘵. 𝘓𝘵𝘥. 𝘜𝘯𝘷𝘦𝘪𝘭𝘴 𝘗𝘪𝘯𝘬 𝘗𝘰𝘵𝘢𝘵𝘰 – 𝘈 𝘊𝘩𝘪𝘤 𝘝𝘦𝘨𝘦𝘵𝘢𝘳𝘪𝘢𝘯 𝘋𝘪𝘯𝘪𝘯𝘨 𝘋𝘦𝘴𝘵𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘗𝘰𝘦𝘴 𝘎𝘢𝘳𝘥𝘦𝘯